Markets
BIO

Imprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13%

Imprimis Pharmaceuticals, Inc.IMMY was a big mover last session, as the company saw its shares rise over 13% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the recent trend of the company, as the stock is now down nearly 15% in the past one-month time frame.

The company has seen one negative estimate revision in the last 30 days and the Zacks Consensus Estimate also moved lower suggesting trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's move higher can last.

Currently, Imprimis Pharmaceuticals carries a Zacks Rank #4 (Sell).

Imprimis Pharmaceuticals, Inc. Price

Imprimis Pharmaceuticals, Inc. Price | Imprimis Pharmaceuticals, Inc. Quote

A better-ranked stock in the same industry is Bio-Rad Laboratories, Inc. BIO , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is IMMY going up? Or down? Predict to see what others think: Up or Down

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report

Imprimis Pharmaceuticals, Inc. (IMMY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BIO

Other Topics

Investing Stocks